Prospective, Multicentre Study to Evaluate the Thrombectomy System for Stroke: iNedit, iNdeep and iNtercept

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

175 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-29

Study Completion Date

2025-02-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

First prospective, single-arm, multicentre study to evaluate the safety and efficacy of the overall stroke thrombectomy system: iNedit, iNdeep and iNtercept in patients with acute ischemic stroke.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety Evaluation of the Thromboaspiration Catheter System iNstroke in Patients With Acute Ischemic Stroke

NCT05720975

Acute Ischemic Stroke

COMPLETED

IMPACT- 24Bt Post Mech. Thrombectomy and/or rtPA TRIAL IMPlant Augmenting Cerebral Blood Flow 24 Hours From Stroke Onset

NCT01874093

Ischemic Stroke

TERMINATED PHASE3

Results of the Use of Two Stentrievers Simultaneosly Compared With One as a Primary Treatment in Acute Ischemic Stroke

NCT05930145

Stroke Thrombectomy Arterial Occlusive Diseases

RECRUITING NA

Hemodynamic Changes in Acute Ischaemic Stroke Patients

NCT05195983

Acute Stroke

UNKNOWN

Endovascular Treatment and RIPC in Acute Ischemic Stroke

NCT04581759

Acute Ischemic Stroke Endovascular Treatment

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, multicentre, single-arm and open-label clinical safety and efficacy research.

The purpose of the study is to evaluate the safety and efficacy of the three devices designed by iVascular for neurothrombectomy (iNedit, iNdeep and iNtercept) used together as a tool to facilitate the placement of the stent retriever and apply temporary restriction of blood flow in patients who have suffered a stroke and who undergo mechanical thrombectomy due to acute large vessel occlusion (LVO), presented within 8 hours from symptoms onset (the last time the patient was seen well).

Being a mechanical thrombectomy the procedure by which the thrombus that occludes a cerebral vessel is accessed. It is accessed through an endovascular catheter, inserted through the femoral artery, for disruption or removal.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental: iNedit, iNdeep, iNtercept

Study devices

iNedit, iNdeep, iNtercept

Intervention Type DEVICE

Patients to undergo mechanical thrombectomy with iNedit, iNdeep and iNtercept

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

iNedit, iNdeep, iNtercept

Patients to undergo mechanical thrombectomy with iNedit, iNdeep and iNtercept

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Clinical:

1. Age ≥18
2. Informed consent signed by the patient or their representative; to use the patient's data
3. Focal disabling neurologic deficit consistent with acute cerebral ischemia.
4. Baseline NIHSS obtained before procedure of ≥6 points and ≤25 points.
5. Pre-stroke mRS score ≤2.
6. Planning to start treatment within 24 hours of symptoms onset, defined as the last time when the patient was seen well (the start of the procedure is defined as arterial puncture).

Neuroimaging criteria:

1. Occlusion (TICI 0 or TICI 1) of the internal intracranial carotid artery, M1 and M2 segments of the middle cerebral artery and T carotid artery, suitable for mechanical thrombectomy confirmed by conventional angiography.
2. For patients treated ≤8 hours:

a) Score 6 to 10 on ASPECTS scale (Alberta Stroke Program Early CT Score).

For patients treated between 8 and 24 hours:

a) "Target Mismatch Profile" on CT perfusion or MRI (ischemic core volume is \<70mL, mismatch ratio is \>1,8 and mismatch volume is \>15 mL).
3. Ability to obtain selective angiography by catheterisation of the target artery.

Exclusion Criteria

Clinical:

1. Patient has suffered a stroke in the past one year.
2. Occlusion (TICI 0 or TICI 1) in vertebrobasilar territory.
3. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.
4. Known hemorrhagic diathesis, coagulaion factor deficiency or oral anti-vitamin K anticoagulant therapy with an INR \>3.0.
5. Blood glucose \<50 mg/dl or \>400 mg/dl. NOTE: If blood glucose can be successfully reduced and maintained at an acceptable level by administering the medication recommended by the ESO (European Stroke Organisation) in its guidelines, the patient may be included.
6. Severe sustained hypertension (systolic pressure \>185 mm Hg or diastolic pressure \>110 mm Hg). NOTE: If blood pressure can be successfully reduced and maintained at an acceptable level by administering the medication recommended by the ESO (European Stroke Organisation) in its guidelines (also IV infusion of antihypertensives), the patient may be included.
7. Serious advanced or terminal illness with anticipated life expectancy of less than six months.
8. History of life-threatening allergy (more than rash) to contrast medium.
9. Known allergy to nickel, prior to treatment.
10. Known renal insufficiency with creatinine ≥3 mg/dl or Glomerular Filtration Rate (GFR) \<30 mL/min.
11. Cerebral vasculitis.
12. Known current cocaine use.
13. Patient who is participating, at the time of inclusion, in a study with a device or drug that could affect this study.
14. Patients who are unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitors from overseas).

Neuroimaging criteria:

1. CT or MRI evidence of hemorrhage (the presence of microbleeds is allowed).
2. Significant mass effect with midline shift.
3. Evidence of complete occlusion, high-grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery (TANDEM lesions).
4. Patients with known or suspected underlying intracranial atherosclerotic lesions responsible for the target occlusion.
5. Patients with occlusions in multiple vascular territories (e.g. bilateral anterior circulation or anterior/posterior circulation).
6. Evidence of intracranial tumour with the exception of asymptomatic meningiomas with no mass effect.
7. Presumed septic embolism with suspected aortic dissection or suspicion of bacterial endocarditis.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No